Athelas vs Eli Lilly

Side-by-side comparison of AI visibility scores, market position, and capabilities

Eli Lilly leads in AI visibility (81 vs 43)
Athelas logo

Athelas

EmergingHealthcare

Remote Patient Monitoring

SF healthcare tech with remote patient monitoring devices and AI medical billing for CCM/RPM programs; $132M General Catalyst and Sequoia backed generating $200-300/month per patient in additional practice revenue.

AI VisibilityBeta
Overall Score
C43
Category Rank
#328 of 596
AI Consensus
84%
Trend
up
Per Platform
ChatGPT
48
Perplexity
43
Gemini
43

About

Athelas is a San Francisco-based healthcare technology company providing remote patient monitoring (RPM) devices and AI-powered medical billing automation for physicians managing patients with chronic conditions — enabling clinics to capture recurring CMS (Centers for Medicare & Medicaid Services) reimbursement for Chronic Care Management (CCM) and Remote Patient Monitoring programs that most practices fail to bill correctly or at all. Founded in 2016 by Tanay Tandon and Deepika Bodapati and backed with $132 million raised from General Catalyst, Sequoia Capital, and others, Athelas serves 1,000+ healthcare provider organizations with cellular-connected monitoring devices and automated billing workflow.

Full profile
Eli Lilly logo

Eli Lilly

LeaderHealthcare

General

Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.

AI VisibilityBeta
Overall Score
A81
Category Rank
#17 of 596
AI Consensus
71%
Trend
stable
Per Platform
ChatGPT
80
Perplexity
75
Gemini
77

About

Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.

Full profile

AI Visibility Head-to-Head

43
Overall Score
81
#328
Category Rank
#17
84
AI Consensus
71
up
Trend
stable
48
ChatGPT
80
43
Perplexity
75
43
Gemini
77
47
Claude
86
48
Grok
85

Key Details

Category
Remote Patient Monitoring
General
Tier
Emerging
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Athelas
Remote Patient Monitoring

Integrations

Eli Lilly is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.